Advanced Proteome Therapeutics (APC) has entered into an agreement for a feasibility study with a global pharmaceutical company interested in evaluating APC’s proprietary crosslinking technologies.
As per the agreement, APC will chemically modify a specified entity by site-specifically attaching it to a variety of carriers that are designed to afford improved properties in clinical settings.
APC has developed technology and filed patent applications to cover its inventions in the area of protein modification which it believes provide important scientific and commercial advantages that could be demonstrated under the terms of the agreement.
APC president and CEO Alexander Krantz said that the agreement is an important step for Advanced Proteome Therapeutics as their scientists have developed several potential drugs and diagnostics that have advanced to testing stages, which have been an outgrowth of the platform technologies.
"The opportunity to apply our platform to a specific initiative of a global pharmaceutical company will accelerate its further development and expand its scope, Krantz said.